Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.SMFR · Entity 1634 | President and COO | December 09, 2021 | December 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date December 09, 2021 · Filed December 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 188,888 |
Reported balance
After 2021-12-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-09 · Grant · Acquired 1,888,888 · Balance 188,888 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time. F2: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing. F3: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 29,021 |
Reported balance
After 2021-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-09 · Grant · Acquired 29,021 · Balance 29,021 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time. F2: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing. F4: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 6,263 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 6 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 41,895 |
Reported balance
After 2021-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-09 · Grant · Acquired 41,895 · Balance 41,895 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time. F2: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing. F5: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 29,196 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 4 vesting periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time.
F2: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing.
F3: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date.
F4: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 6,263 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 6 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date.
F5: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 29,196 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 4 vesting periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2021 Filed Dec 13, 2021 19:09 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 41,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069332 · doc4.xml · derivative · entry 3 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,895 Underlying: Class A Common Stock · 41,895 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time. F2 · derivative.exercise_price: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing. F5 · derivative.exercise_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 29,196 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 4 vesting periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. F5 · derivative.expiration_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 29,196 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 4 vesting periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 19:09 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 29,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069332 · doc4.xml · derivative · entry 2 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,021 Underlying: Class A Common Stock · 29,021 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time. F2 · derivative.exercise_price: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing. F4 · derivative.exercise_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 6,263 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 6 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. F4 · derivative.expiration_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date with respect to 6,263 of the RSUs, and will be satisfied with respect to the remainder of the RSUs over 6 quarterly periods, subject to the Reporting Person's continued service to the Issuer on each service-based vesting date. Read SEC document |
| December 09, 2021 Filed Dec 13, 2021 19:09 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 1,888,888 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069332 · doc4.xml · derivative · entry 1 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,888 Underlying: Class A Common Stock · 188,888 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration, granted pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 9, 2021 (as amended, the "Merger Agreement"), by and among CM Life Sciences, Inc., S-IV Sub, Inc. and Mount Sinai Genomics, Inc. d/b/a Sema4. In addition, in the event that any similar RSUs are forfeited (for example, as a result of the recipient no longer being an employee of the Issuer), the Merger Agreement provides for the shares underlying such forfeited RSUs to become available for issuance to other RSU recipients. Therefore, each RSU also represents to right to receive additional shares of the Issuer's Class A Common Stock from this "forfeiture pool". The number of shares of the Issuer's Class A Common Stock that may be issued to the Reporting Person pursuant to the "forfeiture pool" is not determinable at this time. F2 · derivative.exercise_price: [cont'd from footnote 1] Any shares of the Issuer's Class A Common Stock ultimately issued to the Reporting Person in respect of each RSU will be reported in a subsequent filing. F3 · derivative.exercise_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date. F3 · derivative.expiration_date: The vesting of the RSUs is conditioned on the satisfaction of both a service requirement and a market-based requirement. The service requirement is deemed satisfied as of the grant date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 18:57 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Tax withholdingClass A Common Stock | 2,238 | $5.52 | $12,353.76 |
DisclosureSEC source: 0001209191-21-067987 · doc4.xml · nonDerivative · entry 2 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,903 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover certain tax obligation in connection with the stock bonus granted to the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.51 to $5.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 18:57 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantClass A Common Stock | 8,376 | $6.05 | $50,674.80 |
DisclosureSEC source: 0001209191-21-067987 · doc4.xml · nonDerivative · entry 1 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,141 F1 · shares: The indicated shares were issued to Reporting Person as a stock bonus in connection with the elimination of Issuer's sabbatical leave program, in which all employees of Issuer hired on or before June 30, 2021 were provided an opportunity to receive a stock bonus in lieu of their continued eligibility to take sabbatical leave. The stock bonus was fully vested as of the date of issuance. Read SEC document |
| October 25, 2021 Filed Nov 2, 2021 20:22 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 22,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062551 · doc4.xml · derivative · entry 3 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,768 Underlying: Class A Common Stock · 22,517 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 25, 2021 Filed Nov 2, 2021 20:22 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | SaleClass A Common Stock | 5,752 | $7.54 | $43,370.08 |
DisclosureSEC source: 0001209191-21-062551 · doc4.xml · nonDerivative · entry 2 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,765 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| October 25, 2021 Filed Nov 2, 2021 20:22 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | Exercise / conversionClass A Common Stock | 22,517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-062551 · doc4.xml · nonDerivative · entry 1 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:44 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantRestricted Stock Unit · Derivative | 360,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059757 · doc4.xml · derivative · entry 2 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,285 Underlying: Class A Common Stock · 360,285 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F1 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 21:44 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 240,190 | $0.00 Strike: $7.62 | $0.00 |
DisclosureSEC source: 0001209191-21-059757 · doc4.xml · derivative · entry 1 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,190 Underlying: Class A Common Stock · 240,190 shares Expires 2031-09-30 F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 18:53 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 480,657 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0001209191-21-048230 · doc4.xml · derivative · entry 3 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,657 Underlying: Class A Common Stock · 480,657 shares Expires 2030-02-17 F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards. F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 18:53 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 332,963 | Not disclosed Strike: $0.77 | Not disclosed |
DisclosureSEC source: 0001209191-21-048230 · doc4.xml · derivative · entry 2 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,963 Underlying: Class A Common Stock · 332,963 shares Expires 2030-02-17 F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards. F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 22, 2021 Filed Jul 26, 2021 18:53 UTC | GeneDx Holdings Corp. SMFR · Entity 1634 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,167,093 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001209191-21-048230 · doc4.xml · derivative · entry 1 Coffin James · CIK 0001873883 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,167,093 Underlying: Class A Common Stock · 2,167,093 shares Expires 2027-08-30 F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards. F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.